Please assess the completion status of the following clinical trial:

Trial Title: ELEVATE Early LEvosimendan Vs Usual Care in Advanced Chronic hearT failurE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Systolic dysfunction (LVEF ≤ 35% by echo assessment within 6 months before enrolment)~* No requirement for hospital admission for diagnostic work up or elective treatment to define etiology and/or treatment plan~* Already on optimal standard HF treatment based on individual tolerance, including cardiac resynchronization therapy (CRT)/ICD device according to current guidelines~* At least 2 hospital admissions for HF in the 6 months before enrolment, the most recent one within 30-90 days before enrolment with requirement for inotrope administration~Exclusion Criteria:~* Participant in other studies in the last 30 days~* Life expectancy \< 1 year for comorbid conditions other than HF~* Pregnancy, lactation, childbearing potential unless on adequate contraception~* Acute coronary syndromes, percutaneous or surgical revascularization, valve surgery performed within 8 weeks before enrolment~* Planned percutaneous or surgical procedures (except for heart transplantation)~* CRT within 6 months before enrolment~* Cardiogenic shock~* Supine systolic BP \< 85 mmHg~* Severe liver insufficiency (\>three-fold increase in AST-ALT )~* Sever chronic kidney dysfunction (estimated GFR \< 30 ml/min)~* Sustained ventricular tachycardia~* Severe chronic or current acute infection (temperature \>38 C, WBC \>15,000/mm3)~* Severe chronic obstructive pulmonary disease (FEV1 \<30% predicted or on oxygen therapy)~* Severe persistent anemia (Hb \< 10 g/l))~* ACHF exacerbation due to conditions requiring specific treatment (e.g. anemia, atrial fibrillation, supraventricular tachycardia ) Documented low compliance or unavailable for programmed follow-up visits and phone contact

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Diuretics (Type: ACTIVE_COMPARATOR): Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
- Levosimendan (Type: EXPERIMENTAL): Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~* SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~* SBP ≥100 mmHg: 0.1 mcg/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).